Axsome Therapeutics
AXSM
409 hedge funds and large institutions have $6.41B invested in Axsome Therapeutics in 2026 Q1 according to their latest regulatory filings, with 71 funds opening new positions, 145 increasing their positions, 142 reducing their positions, and 52 closing their positions.
37% more first-time investments, than exits
New positions opened: 71 | Existing positions closed: 52
28% more call options, than puts
Call options by funds: $140M | Put options by funds: $110M
3% more funds holding
Funds holding: 398 → 409 (+11)
2% more repeat investments, than reductions
Existing positions increased: 145 | Existing positions reduced: 142
0.55% less ownership
Funds ownership: 74.66% → 74.11% (-0.55%)
7% less capital invested
Capital invested by funds: $6.86B → $6.41B (-$457M)
31% less funds holding in top 10
Funds holding in top 10: 13 → 9 (-4)
Top Buyers
Top Sellers
AXSM Hedge Fund Activity: Q1 2026 in Review
409 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q1 2026, worth a combined $6.41B — down 6.7% from $6.86B a quarter earlier.
Buyers outnumbered sellers: 71 funds opened new AXSM positions and 52 closed out — a net gain of 19 holders — while 145 added to existing stakes and 142 trimmed.
The largest buyer was First Trust Advisors, adding an estimated $92.2M. The largest seller was RTW Investments, exiting entirely with an estimated $162M sold.
- 409 institutional investors held Axsome Therapeutics (AXSM) as of Q1 2026, up from 398 in Q4 2025.
- Funds reported $6.41B of Axsome Therapeutics stock for Q1 2026, down 6.7% quarter-over-quarter.
- 71 funds opened new Axsome Therapeutics positions in Q1 2026 and 52 closed out, a net change of +19 holders.
- The largest Axsome Therapeutics buyer in Q1 2026 was First Trust Advisors, an estimated $92.2M added.
- The largest Axsome Therapeutics seller in Q1 2026 was RTW Investments, an estimated $162M sold.
Based on aggregated 13F filings for Q1 2026.